Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.

@article{Mandler2000ImmunoconjugatesOG,
  title={Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines.},
  author={Raya Mandler and C Wu and Edward A. Sausville and A J Roettinger and David J. Newman and Daniel Ka-Chun Ho and C. Richter King and Dajun Yang and Marc E. Lippman and Nicholas F. Landolfi and Ekaterina A Dadachova and Martin W. Brechbiel and Thomas A. Waldmann},
  journal={Journal of the National Cancer Institute},
  year={2000},
  volume={92 19},
  pages={1573-81}
}
BACKGROUND HER2 is a membrane receptor whose overexpression is strongly associated with poor prognosis in breast carcinomas. Inhibition of HER2 activity can reduce tumor growth, which led to the development of Herceptin, an anti-HER2 monoclonal antibody (MAb) that is already in clinical use. However, the objective response rate to Herceptin monotherapy is quite low. HER2 activity can also be inhibited by the highly cytotoxic antibiotic geldanamycin (GA). However, GA is not used clinically… CONTINUE READING
22 Extracted Citations
39 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 22 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 39 references

Preclinical and clinical study of HER2targeting cancer gene therapy

  • MC Hung, JY Chang, XM. Xing
  • Adv Drug Delivery Rev 1998;30:219–27
  • 1998

Similar Papers

Loading similar papers…